ReviewACS omega2026
Toward a Mechanistic Framework for Intestinal Drug Permeability: Integrating
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Predicting oral bioavailability remains a central challenge in pharmaceutical sciences, primarily limited by the phenomenological nature of traditional predictive models that provide correlations without mechanistic insight. While molecular dynamics (MD) simulations provide detailed atomistic insights into drug-membrane interactions, they require rigorous experimental validation. Conversely, biorelevant assayssuch as Caco-2 monolayers and everted gut sacssupply essential biological end points but with limited mechanistic granularity. This review systematically evaluates the strengths and limitations of disparate approaches, from static quantitative structure-property relationship (QSAR) models to physics-based molecular simulations. We propose an integrated framework that synergistically combines the physical resolution of multiscale MD modeling with the biological relevance of hierarchical experimental validation. Using a representative molecule with a divergent pharmacokinetic profilecharacterized by high predicted permeability yet substantial metabolic instabilityas an exemplary case, we present a mechanistic workflow for resolving such discrepancies. This integrated approach transforms the validation process from a binary outcome into a diagnostic tool for mechanistic deconstruction, ultimately guiding the rational design of next-generation orally bioavailable therapeutics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.